'On consolidated basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of Sun Pharmaceutical Industries has increased 8.93% to Rs 14478.31 crore. Operating profit margin has jumped from 29.64% to 31.27%, leading to 14.93% rise in operating profit to Rs 4,527.05 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 12.50% to 11.42%. Purchase of finished goods cost rose from 6.67% to 7.66%. Employee cost increased from 18.90% to 19.46%. Other expenses fell from 31.89% to 29.59%. Loss on forex transaction rose from 0.98% to 3.03%.
Other income rose 32.75% to Rs 469.92 crore. PBIDT rose 16.40% to Rs 4996.97 crore. Provision for interest rose 44.37% to Rs 99.86 crore. Loan funds rose to Rs 5,215.10 crore as of 30 September 2025 from Rs 2,57...
Pleaselogin & subscribe to view the full report.
More Reports
|
|